Literature DB >> 28475775

Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma.

Manuela Silginer1, Sara Nagy1, Caroline Happold1, Hannah Schneider1, Michael Weller1, Patrick Roth1.   

Abstract

BACKGROUND: Interferons (IFNs) are cytokines typically induced upon viral infection but are constitutively expressed also in the absence of acute infection. The physiological role of autocrine and paracrine IFN signaling, however, remains poorly understood, and its function in glioblastoma has not been explored in depth.
METHODS: Using RNA interference-mediated gene silencing, we characterized constitutive type I IFN signaling and its role in human glioma cells.
RESULTS: We observed constitutive expression of phosphorylated signal transducer and activator of transcription 1 (pSTAT1) and myxovirus resistance protein A (MxA), a classical IFN-response marker, in the absence of exogenous IFN-β. In vivo, we found higher MxA expression in gliomas than in normal tissue, suggesting that IFN signaling is constitutively active in these tumors. To demonstrate the presence of an autocrine type I IFN signaling loop in glioma cells in vitro, we first confirmed the expression of the type I alpha/beta receptor (IFNAR)1/2, and its ligands, IFN-α and IFN-β. Small interfering RNA-mediated receptor gene silencing resulted in reduced expression of MxA at mRNA and protein levels, as did gene silencing of the ligands, corroborating the hypothesis of an autocrine signaling loop in which type I IFNs induce intracellular signaling through IFNAR1/2. On a functional level, following IFNAR1 or IFNAR2 gene silencing, we observed reduced programmed death ligand 1 (PD-L1) and major histocompatibility complex (MHC) class I and II expression as well as an enhanced susceptibility to natural killer immune cell lysis, suggesting that autocrine IFN signaling contributes to the immune evasion of glioma cells.
CONCLUSIONS: Our findings point to an important role of constitutive IFN signaling in glioma cells by modulating their interaction with the microenvironment.
© The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  PD-L1; STAT1; glioma; immunogenicity; interferon

Mesh:

Substances:

Year:  2017        PMID: 28475775      PMCID: PMC5596176          DOI: 10.1093/neuonc/nox051

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  42 in total

Review 1.  A weak signal for strong responses: interferon-alpha/beta revisited.

Authors:  T Taniguchi; A Takaoka
Journal:  Nat Rev Mol Cell Biol       Date:  2001-05       Impact factor: 94.444

Review 2.  Mechanisms of type-I- and type-II-interferon-mediated signalling.

Authors:  Leonidas C Platanias
Journal:  Nat Rev Immunol       Date:  2005-05       Impact factor: 53.106

Review 3.  Interferon signalling network in innate defence.

Authors:  Akinori Takaoka; Hideyuki Yanai
Journal:  Cell Microbiol       Date:  2006-06       Impact factor: 3.715

Review 4.  STAT signaling in glioma cells.

Authors:  Karolina Swiatek-Machado; Bozena Kaminska
Journal:  Adv Exp Med Biol       Date:  2013       Impact factor: 2.622

5.  Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma.

Authors:  L H Wong; K G Krauer; I Hatzinisiriou; M J Estcourt; P Hersey; N D Tam; S Edmondson; R J Devenish; S J Ralph
Journal:  J Biol Chem       Date:  1997-11-07       Impact factor: 5.157

6.  Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.

Authors:  Kazuya Motomura; Atsushi Natsume; Yugo Kishida; Hiroyuki Higashi; Yutaka Kondo; Yoko Nakasu; Tatsuya Abe; Hiroki Namba; Kenji Wakai; Toshihiko Wakabayashi
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860

7.  IFNalpha activates dormant haematopoietic stem cells in vivo.

Authors:  Marieke A G Essers; Sandra Offner; William E Blanco-Bose; Zoe Waibler; Ulrich Kalinke; Michel A Duchosal; Andreas Trumpp
Journal:  Nature       Date:  2009-02-11       Impact factor: 49.962

Review 8.  Glioma.

Authors:  Michael Weller; Wolfgang Wick; Ken Aldape; Michael Brada; Mitchell Berger; Stefan M Pfister; Ryo Nishikawa; Mark Rosenthal; Patrick Y Wen; Roger Stupp; Guido Reifenberger
Journal:  Nat Rev Dis Primers       Date:  2015-07-16       Impact factor: 52.329

9.  STAT1 pathway mediates amplification of metastatic potential and resistance to therapy.

Authors:  Nikolai N Khodarev; Paul Roach; Sean P Pitroda; Daniel W Golden; Mihir Bhayani; Michael Y Shao; Thomas E Darga; Mara G Beveridge; Ravi F Sood; Harold G Sutton; Michael A Beckett; Helena J Mauceri; Mitchell C Posner; Ralph R Weichselbaum
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

10.  MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape.

Authors:  Paula Codo; Michael Weller; Gunter Meister; Emese Szabo; Alexander Steinle; Marietta Wolter; Guido Reifenberger; Patrick Roth
Journal:  Oncotarget       Date:  2014-09-15
View more
  22 in total

1.  Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma.

Authors:  Chen Zhu; Cunyi Zou; Gefei Guan; Qing Guo; Zihao Yan; Tianqi Liu; Shuai Shen; Xiaoyan Xu; Chen Chen; Zhiguo Lin; Wen Cheng; Anhua Wu
Journal:  Oncoimmunology       Date:  2019-06-12       Impact factor: 8.110

2.  Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas.

Authors:  Daniëlle Verver; Vichnou Poirier-Colame; Gorana Tomasic; Khadija Cherif-Rebai; Dirk J Grunhagen; Cornelis Verhoef; Stefan Suciu; Caroline Robert; Laurence Zitvogel; Alexander M M Eggermont
Journal:  Oncoimmunology       Date:  2019-09-06       Impact factor: 8.110

3.  Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma.

Authors:  Arko Sen; Briana C Prager; Cuiqing Zhong; Donglim Park; Zhe Zhu; Ryan C Gimple; Qiulian Wu; Jean A Bernatchez; Sungjun Beck; Alex E Clark; Jair L Siqueira-Neto; Jeremy N Rich; Graham McVicker
Journal:  Cancer Res       Date:  2021-12-13       Impact factor: 13.312

4.  Allicin Inhibits Proliferation by Decreasing IL-6 and IFN-β in HCMV-Infected Glioma Cells.

Authors:  Zelin Yang; Jizao Du; Jinjin Zhu; Yuxi Rong; Shaohuai Chen; Lisheng Yu; Xiangyang Deng; Xiaojia Zhang; Hansong Sheng; Liang Yang; Xiangqi Lu; Dandong Li; Bo Yin; Jian Lin
Journal:  Cancer Manag Res       Date:  2020-08-17       Impact factor: 3.989

5.  Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer.

Authors:  In Hye Song; Young-Ae Kim; Hyeonjin Lee; Hye Seon Park; In Ah Park; Chan Kyu Sim; Myeong Sup Lee; Gyungyub Gong; Hee Jin Lee
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

6.  Rapid 3D Bioprinting of Glioblastoma Model Mimicking Native Biophysical Heterogeneity.

Authors:  Min Tang; Shashi Kant Tiwari; Kriti Agrawal; Matthew Tan; Jason Dang; Trevor Tam; Jing Tian; Xueyi Wan; Jacob Schimelman; Shangting You; Qinghui Xia; Tariq M Rana; Shaochen Chen
Journal:  Small       Date:  2021-01-27       Impact factor: 13.281

7.  Identification of the immune gene expression signature associated with recurrence of high-grade gliomas.

Authors:  Adria-Jaume Roura; Bartlomiej Gielniewski; Paulina Pilanc; Paulina Szadkowska; Marta Maleszewska; Sylwia K Krol; Ryszard Czepko; Wojciech Kaspera; Bartosz Wojtas; Bozena Kaminska
Journal:  J Mol Med (Berl)       Date:  2020-11-19       Impact factor: 4.599

8.  Interferon-alpha enhances the antitumour activity of EGFR-targeted therapies by upregulating RIG-I in head and neck squamous cell carcinoma.

Authors:  Hailong Ma; Shufang Jin; Wenyi Yang; Ge Zhou; Mei Zhao; Sijie Fang; Zhiyuan Zhang; Jingzhou Hu
Journal:  Br J Cancer       Date:  2018-01-18       Impact factor: 7.640

9.  Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma.

Authors:  Yasuo Takashima; Atsushi Kawaguchi; Tomohiko Kanayama; Azusa Hayano; Ryuya Yamanaka
Journal:  Oncotarget       Date:  2018-04-10

10.  Glioma stem-like cells evade interferon suppression through MBD3/NuRD complex-mediated STAT1 downregulation.

Authors:  Xiaoyan Zhan; Saisai Guo; Yuanyuan Li; Haowen Ran; Haohao Huang; Lanjuan Mi; Jin Wu; Xinzheng Wang; Dake Xiao; Lishu Chen; Da Li; Songyang Zhang; Xu Yan; Yu Yu; Tingting Li; Qiuying Han; Kun He; Jiuwei Cui; Tao Li; Tao Zhou; Jeremy N Rich; Shideng Bao; Xuemin Zhang; Ailing Li; Jianghong Man
Journal:  J Exp Med       Date:  2020-05-04       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.